MA53511A - Schéma de traitement en cas de doses oubliées pour des esters de palipéridone injectables à action prolongée - Google Patents

Schéma de traitement en cas de doses oubliées pour des esters de palipéridone injectables à action prolongée

Info

Publication number
MA53511A
MA53511A MA053511A MA53511A MA53511A MA 53511 A MA53511 A MA 53511A MA 053511 A MA053511 A MA 053511A MA 53511 A MA53511 A MA 53511A MA 53511 A MA53511 A MA 53511A
Authority
MA
Morocco
Prior art keywords
acting
injection
long
treatment regimen
dose treatment
Prior art date
Application number
MA053511A
Other languages
English (en)
Other versions
MA53511B1 (fr
Inventor
Srihari Gopal
Paulien Gerarda Maria Ravenstijn
Alberto Russu
Mahesh Narain Samtani
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Priority claimed from PCT/US2016/024841 external-priority patent/WO2016164218A1/fr
Publication of MA53511A publication Critical patent/MA53511A/fr
Publication of MA53511B1 publication Critical patent/MA53511B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA53511A 2015-04-07 2016-03-30 Schéma de traitement en cas de doses oubliées pour des esters de palipéridone injectables à action prolongée MA53511B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562144054P 2015-04-07 2015-04-07
PCT/US2016/024841 WO2016164218A1 (fr) 2015-04-07 2016-03-30 Schéma de traitement en cas de doses oubliées pour des esters de palipéridone injectables à action prolongée

Publications (2)

Publication Number Publication Date
MA53511A true MA53511A (fr) 2021-09-15
MA53511B1 MA53511B1 (fr) 2023-12-29

Family

ID=89428893

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53511A MA53511B1 (fr) 2015-04-07 2016-03-30 Schéma de traitement en cas de doses oubliées pour des esters de palipéridone injectables à action prolongée

Country Status (1)

Country Link
MA (1) MA53511B1 (fr)

Also Published As

Publication number Publication date
MA53511B1 (fr) 2023-12-29

Similar Documents

Publication Publication Date Title
EP3280416A4 (fr) Schéma de traitement en cas de doses oubliées pour des esters de palipéridone injectables à action prolongée
SI3936130T1 (sl) Režim odmerjanja valbenazina za zdravljenje hiperkinetičnih gibalnih motenj
IL263538A (en) Radio-pharmaceutical complexes
EP3413963A4 (fr) Accès à un site de traitement intravasculaire
EP4098297C0 (fr) Dispositif d'obtention des doses pour seringues
HUE062158T2 (hu) EZH2 inhibitorok a limfóma kezelésére
FR3016868B1 (fr) Article a dose unitaire
DK3272338T3 (da) Oral doseringsform for ketamin
EP3320521A4 (fr) Indicateur thérapeutique atomique
IL266171A (en) Dosage and therapeutic regimen for hdm2-p53 interaction inhibitors
IL247721A0 (en) Pharmaceutical preparations containing active medicinal compounds for the treatment of solid tumors
EP3217915C0 (fr) Machine permettant de compter des articles médicaux et procédé correspondant
DK3368017T3 (da) Optimeret mesalazinholdig højdosistablet
IL253439A0 (en) Add-on radiosynthesiser device
EP3432901A4 (fr) Traitement anticancéreux séquentiel
ZA201803010B (en) Plasminogen dosage regimen for wound healing
EP3395350A4 (fr) Médicament pour le traitement des infarctus cérébraux
MA53511A (fr) Schéma de traitement en cas de doses oubliées pour des esters de palipéridone injectables à action prolongée
MA41544A (fr) Dosages de panobinostat pour le traitement du myélome multiple
GB201614179D0 (en) Dosage regimen for the treatment of endometriosis
FR3024036B1 (fr) Composes volatils pour le traitement du neuropaludisme
GB201500383D0 (en) Apparatus for treatment of radioactive materials
IT201600129151U1 (it) Contenitore antipuntura per aghi di siringhe usate
TH1601003393A (th) รูปแบบปริมาณที่ให้ทางเภสัชกรรม
GB201600179D0 (en) Apparatus for treatment of radioactive materials